Press Release

2026 CL7 Research Grant Award Recipients

Published on
March 26, 2026

On this opening day of major league baseball, let’s applaud the new team of CL7 Research Grant Award Recipients.

We received an unprecedented 18 submissions this year which is a 100% increase from the prior year.

Demand for cure is accelerating and so is HOPE for a breakthrough. The Charlie Landers Foundation (CL7) has committed to funding $496,845 as part of our fourth round of research grants.

We are profoundly grateful to the following investigators for their ideas, focus and compassion as they look to strike out Ewing’s Sarcoma and as always, we are indebted to our CL7 Medical Advisory board for making these determinations.

HUGE thanks to our CL7 community both near and far for making our grant cycles possible. Thank you for walking alongside us as we honor Charlie’s mission to help others going through what he did.

Let’s play ball!

Dr. Colleen Delaney - “Universal Allogeneic STEAP1 CAR-NK Cell Therapy for Ewing Sarcoma”

Seattle Children’s Research Institute - $150,000

Dr. Yuan Gao, PHD - “Therapeutically Targeting Lipid Metabolism to Overcome Vulnerabilities in Ewing Sarcoma”

Case Western Reserve University School of Medicine - $112,000

Juan Vasquez, MD - “Tumor targeted delivery of exatecan with pH-sensitive peptides in Ewing Sarcoma”

Yale University - $96,426

Benjamin Sunkel, PhD - “Investigating NR2C2 as a Therapeutic Target in Ewing Sarcoma”

Research Institute at Nationwide Children’s Hospital - $138,419

Short heading goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Category
5 min read

Blog title heading will go here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.
Category
5 min read

Blog title heading will go here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.
Category
5 min read

Blog title heading will go here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.